Table 2 Association between BMI and clinical-molecular features (N = 54)
BMI | Chi2 Test | ||
|---|---|---|---|
<25 | ≥25 | p-value | |
N (%) | N (%) | ||
Age at diagnosis | |||
< 49 | 20 (80.0) | 5 (20.0) | 0.002 |
≥ 49 | 11 (37.9) | 18 (62.1) | |
Stage | |||
II | 12 (66.7) | 6 (33.3) | 0.331 |
III | 19 (52.8) | 17 (47.2) | |
Grade | |||
1–2 | 13 (59.1) | 9 (40.9) | 0.836 |
3 | 18 (56.3) | 14 (43.8) | |
Ki-67 | |||
Low | 15 (60.0) | 10 (40.0) | 0.721 |
High | 16 (55.2) | 13 (44.8) | |
Chemotherapy | |||
Sequential | 27 (57.4) | 20 (42.6) | 0.999a |
Concomitant | 4 (57.1) | 3 (42.9) | |
pCR | |||
No | 19 (51.4) | 18 (48.6) | 0.184 |
Yes | 12 (70.6) | 5 (29.4) | |
γ-H2AX | |||
Low | 16 (64.0) | 9 (36.0) | 0.363 |
High | 15 (51.7) | 14 (48.3) | |
pChk1 | |||
Neg | 12 (75.0) | 4 (25.0) | 0.090 |
Pos | 19 (50.0) | 19 (50.0) | |